Day One Biopharmaceuticals (DAWN)
(Real Time Quote from BATS)
$6.49 USD
-0.16 (-2.41%)
Updated Aug 4, 2025 10:24 AM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DAWN 6.49 -0.16(-2.41%)
Will DAWN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DAWN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DAWN
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
DAWN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect
Other News for DAWN
Earnings To Watch: Day One Biopharmaceuticals Inc (DAWN) Reports Q2 2025 Result
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
BlackRock, Inc. Reduces Stake in Day One Biopharmaceuticals Inc
AMG TimesSquare Small Cap Growth Fund Q1 2025 Commentary